Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T21:50:55.420Z.
Calculation as of: 2026-10-06T21:50:55.420Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5a07c8f3a2ad440f5573aff218b3c7846d0d7de427c85f66d5927069d9df71be
PEG RATIO
N/A
BioCardia, Inc.
Market Cap
$15.78M
PEG Ratio
N/A
| NAME | MARKET CAP | PEG RATIO |
|---|---|---|
| BioCardia, Inc. (BCDA) | $15.78M | N/A |
| Allarity Therapeutics, Inc. (ALLR)vs › | $15.68M | N/A |
| Jin Medical International Ltd. (ZJYL)vs › | $15.58M | N/A |
| Cocrystal Pharma, Inc. (COCP)vs › | $15.30M | N/A |
| Dyadic International, Inc. (DYAI)vs › | $16.52M | N/A |
| Pasithea Therapeutics Corp. (KTTA)vs › | $14.94M | N/A |
| Bionano Genomics, Inc. (BNGO)vs › | $16.64M | N/A |
| Palatin Technologies, Inc. (PTN)vs › | $16.74M | N/A |
| TScan Therapeutics, Inc. (TCRX)vs › | $16.82M | N/A |
| Karyopharm Therapeutics Inc. (KPTI)vs › | $14.73M | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
